Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by State Street Corp

State Street Corp reduced its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 8.8% during the 3rd quarter, Holdings Channel reports. The fund owned 1,113,590 shares of the company’s stock after selling 107,786 shares during the quarter. State Street Corp’s holdings in Keros Therapeutics were worth $64,666,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in KROS. KBC Group NV lifted its holdings in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new stake in Keros Therapeutics in the 3rd quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Keros Therapeutics during the 2nd quarter valued at about $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics in the 3rd quarter worth approximately $213,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

KROS has been the topic of several recent research reports. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. Scotiabank decreased their target price on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a report on Friday, December 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Oppenheimer reduced their price objective on shares of Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $81.33.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $17.13 on Thursday. The stock has a market cap of $693.88 million, a price-to-earnings ratio of -3.29 and a beta of 1.20. The business has a 50 day simple moving average of $56.64 and a 200 day simple moving average of $52.06. Keros Therapeutics, Inc. has a 52 week low of $15.67 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter last year, the business posted ($1.33) EPS. The firm’s revenue was up 4750.0% compared to the same quarter last year. On average, analysts predict that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.